#USA #New Orleans #Verismo Therapeutics #SynKIR-310 #KIR-CAR

Verismo Therapeutics Showcases Robust Results for SynKIR™-310

Verismo Therapeutics, a trailblazer in CAR T cell therapies, is set to present exciting interim clinical data for its innovative product, SynKIR™-310, at the upcoming 68th American Society of Hematology (ASH) Annual Meeting, scheduled for December 12-15, 2026, in New Orleans. This groundbreaking therapy, designed for treating relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), employs a multi-chain KIR-CAR platform that enhances therapeutic efficacy while maintaining a favorable safety profile.

Promising Efficacy and Safety Profile

The interim data from the ongoing Phase 1 CELESTIAL-301 trial (NCT06544265) reveal that SynKIR™-310 demonstrates notable antitumor activity. Among the five evaluable patients at the initial dose levels, four achieved positive responses, resulting in an overall objective response rate of 80%. Furthermore, a significant 60% of these patients experienced complete responses, with one individual still maintaining a complete response at the 12-month assessment. This is a remarkable advancement, especially considering that traditional therapies often face challenges with side effects such as CRS (cytokine release syndrome) or ICANS (immune effector cell-associated neurotoxicity syndrome).

In a remarkable highlight, no cases of CRS, ICANS, or DLT (dose-limiting toxicities) were reported across the first two doses of SynKIR™-310. The first two dose levels encompassed outpatient treatments, demonstrating the potential for a less hospital-centric approach in CAR T therapy. This promising safety profile represents a pivotal milestone that could reshape treatment standards in hematological malignancies.

Innovations in Targeting

At ASH 2026, Verismo is not only discussing clinical results. They will also introduce two preclinical posters that delve into advancements within the KIR-CAR platform. The first poster presents a novel dual-targeted KIR-CAR aimed at enhancing treatment responses for lymphomas characterized by variability in antigen expression. This innovation addresses a common challenge faced by existing CD19-targeted therapies, showcasing its ability to combat antigen heterogeneity.

The second preclinical study provides a head-to-head comparative analysis between SynKIR™-310 and single-chain CAR T designs. Preliminary results suggest that SynKIR™-310 delivered superior tumor control while exhibiting considerably lower levels of cytokine production, addressing therapeutic safety concerns more effectively than prior CAR T therapies.

The Future of KIR-CAR Therapy

The KIR-CAR platform, upon which SynKIR™-310 is built, represents a paradigm shift in CAR T technologies. Characterized by its multi-chain architecture, it is capable of circumventing some intrinsic weaknesses of traditional CAR therapies, notably by maintaining T cell functionality and resilience against tumor-induced exhaustion. Importantly, this framework offers a unique bifurcation of target binding and T cell activation signals, enhancing overall patient outcomes.

Verismo Therapeutics is dedicated to tackling significant unmet medical needs in cancer therapy with the KIR-CAR technology. Their dual focus on enhancing patient safety and treatment efficacy in solid and hematologic tumors positions them as leaders in the next generation of immunotherapy. As they prepare for the ASH Annual Meeting, expectations run high for the remarkable therapeutic potential that SynKIR™-310 reveals, and it raises hopes for many seeking innovative solutions in cancer treatment.

With the oral presentation scheduled for December 13, 2026, led by Dr. Michael Tees from the Colorado Blood Cancer Institute, the presentation is highly anticipated within the scientific community and beyond. As Verismo continues to push the boundaries of what is possible in CAR T therapy, clinicians and patients alike eagerly await further data to reshape the landscape of oncology treatments.

Conclusion

The innovative work by Verismo Therapeutics, particularly the advances reflected in SynKIR™-310, signals a new era in CAR T cell therapies. By holding to stringent safety measures while pursuing robust therapeutic efficacy, they are charting a promising path forward in the fight against complex hematologic malignancies. With the imminent insights from the ASH Annual Meeting, the future looks brighter for patients enduring the hardships of tumors that have proven resistant to conventional treatments.